$IDYA — FinTwit mentions on Surfaced

$IDYA — FinTwit mentions on Surfaced

Recent mentions

18 mentions

@jacobpliethJun 10, 2026 · 11:09 AM

What a week so far: $RHHBY $NRIX deal $JNJ buys Firefly $GSK buys $NUVL $PBLS $770m IPO + $100m placement $TRLN going public by reverse merger ($900m cash) $TNGX $600m secondary $IDYA $300m secondary (on the back of Tango) $SMMT $575m secondary (on disappointing #ASCO26 data)

@jacobpliethJun 1, 2026 · 2:12 PM

Boo $IDYA #Asco26 https://t.co/gI1bNua1Fw

@jacobpliethJun 1, 2026 · 1:31 PM

$RVMD $SMMT $BNTX $AZN $MRK $BMY $LLY $IDYA $JNJ $GILD $INCY $PFE $NVS $AVBP #Asco26

@jacobpliethJun 1, 2026 · 12:19 PM

#ASCO26 late-breaker on $IDYA Optimum-02 study is now live: repeats earlier disclosed PFS data, says nothing about OS. Some detail about safety. Presentation in 40 mins.

@jacobpliethApr 30, 2026 · 2:50 PM

@ablT315I @adamfeuerstein Can you comment on the #ASCO26 embargo discipline being shown by $IDYA & $KPTI ?

@jacobpliethApr 23, 2026 · 8:48 AM

Given how much $IDYA has already released (ORR, PFS, stats, PFS curves) I'm a little surprised #ASCO26 is OK with giving it a late-breaker.

@jacobpliethApr 13, 2026 · 2:12 PM

Optimum-02 virtually replicates Optimum-01, and $IDYA heads for US filing. Via @APEXONCo -> https://t.co/y6X9Hs5kKf

@jacobpliethApr 13, 2026 · 1:21 PM

@omphalos007 @avidresearch That probably makes an $IMCR vs $IDYA comparison on PFS alone slightly unfair.

@jacobpliethApr 13, 2026 · 12:39 PM

@avidresearch Kimmtrak is weird - nice OS benefit, hardly anything on PFS. I can't recall why at this point $IMCR $IDYA

@jacobpliethApr 13, 2026 · 12:22 PM

$IDYA PFS curves from Optimum-02 https://t.co/h4ZYytTrsc

@jacobpliethApr 13, 2026 · 11:08 AM

Let's remember again that $NVS dumped off darovasertib for $2.5m in cash + $3.5m in $IDYA series B preferred stock.

@jacobpliethApr 13, 2026 · 10:08 AM

$IDYA darovasertib data from registrational Optimum-02 trial in uveal melanoma are out. What to look for: https://t.co/1LQa0X6xJa

@jacobpliethApr 10, 2026 · 8:18 PM

This is getting quite tiresome: first $ORIC, now $ALLO & $IDYA. Why are you sitting on market-sensitive data rather than releasing it now? https://t.co/N8q95re7ho

@jacobpliethOct 22, 2025 · 1:24 PM

Who won #ESMO25 and who lost? Via @ApexOnco https://t.co/EWzHIIH1Ck $IOBT $CELC $RCUS $CGEM $IDYA $NUVL $AGEN $GILD $DSNKY $INCY $CATX $LPTX $OLMA $SMMT $AVBP $GMAB $EXEL $CGEN $ZLAB $RHHBY

@jacobpliethOct 18, 2025 · 4:44 PM

Novel synthetic lethality approaches from Synnovation, Artios & $NVS leave much to prove. Via @ApexOnco at #ESMO25 -> https://t.co/B5FWHlomX6 $IDYA $RPTX $GSK

@jacobpliethOct 13, 2025 · 2:19 PM

@jeromeleonard5 @NotthatkindofDr At #Jefferies24 $IDYA said data were expected at a medical conf in 2025, if I recall.

@jacobpliethOct 13, 2025 · 2:13 PM

@jeromeleonard5 @NotthatkindofDr GSK4418959 / IDE275? I was kind of hoping to see FIH data on that at #ESMO25 $GSK $IDYA

@jacobpliethSep 8, 2025 · 1:07 PM

If you're catching up with #WCLC25 news, @ApexOnco coverage can be found here: https://t.co/Jl2xGAtcZw $SMMY $IDYA $AZN $JNJ $BMY $ZLAB $BNTX